<DOC>
	<DOCNO>NCT02766621</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability pharmacokinetics escalate single multiple intravenous ( IV ) infusion subcutaneous ( SC ) injection PF 06823859 healthy subject .</brief_summary>
	<brief_title>Evaluation Of Safety , Tolerability And Pharmacokinetics Of Single And Multiple Doses Of Compound PF-06823859</brief_title>
	<detailed_description />
	<criteria>1 . Healthy female subject non childbearing potential male subject , time screening , age 18 55 year , inclusive . Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12 lead ECG clinical laboratory test . 2 . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . 1 . History active latent tuberculosis ( TB ) regardless treatment ; positive Quantiferon TB test . 2 . Subjects history autoimmune disorder . 3 . Subjects history positive result follow serological test : Hepatitis B surface antigen ( HBsAg ) , Hepatitis B core antibody ( HBcAb ) , anti Hepatitis C antibody ( HCVAb ) human immunodeficiency virus ( HIV ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>First human , Phase 1 , Healthy volunteer</keyword>
</DOC>